NeoPharm to present liposome technology data.NeoPharm, Inc. (Lake Forest, IL) announced that six peer-reviewed abstracts will be presented at upcoming scientific meetings. The data will highlight various preclinical and clinical results employing the company's unique and proprietary NeoLipid liposomal technology. Imran Ahmad, PhD, NeoPharm's Chief Scientific Officer and Senior Vice President - Research and Development, recently outlined the company's NeoLipid pipeline at the state-of-the-art Lipids and Biomembranes: New Technologies Symposium in Davos, Switzerland. Dr. Ahmad's presentation was focused on the development of the anti-cancer agent LE-SN38, a NeoLipid product being developed by NeoPharm that is about to begin Phase I clinical trials in humans. "The combination of NeoPharm's state-of-the-art research and development facility, experienced scientists, external research collaborations and solid financial position have helped us to create our large and diverse product pipeline. Furthermore, it is critical that data culminating from these efforts be reviewed and discussed in an open, objective forum," said Dr. Ahmad. The following list outlines the fourth quarter presentation schedule for data on investigational products using the NeoLipid platform: Sunday, October 20 - European Society of Medical Oncology (ESMO ESMO European Society for Medical Oncology ESMO European Student Moon Orbiter ESMO Earth Science Mission Operations ESMO Excited-State Molecular Orbital ), Nice, France Phase I Study of Liposome liposome (lī`pəsōm', lĭp`ə–), microscopic, fluid-filled pouch whose walls are made of layers of phospholipids identical to the phospholipids that make up cell membranes. Encapsulated Mitoxantrone (LEM) in Patients with Advanced Cancers (poster presentation) Tuesday, October 22 - American College American College is the name of:
ACCP American College of Clinical Pharmacy ACCP Army Correspondence Course Program ACCP Atlantic Climate Change Program ACCP Association of Caribbean Commissioners of Police ACCP Assembly of Caribbean Community Parliamentarians ), Albuquerque, New Mexico “Albuquerque” redirects here. For other uses, see Albuquerque (disambiguation). Albuquerque (pronounced [ˈæl.bə.kɚ.kiː], Spanish: [al.βu. Liposome-Encapsulated c-raf Antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). Oligonucleotide (LErafAON) in Patients with Advanced Solid Tumors: Phase I Study of Daily Infusion during Radiation Therapy (ASCO ASCO American Society of Clinical Oncology ASCO Association of Schools and Colleges of Optometry (since 1941; Rockville, Maryland) ASCO Australian Standard Classification of Occupations ASCO Automatic Switch Company encore poster presentation) Wednesday, November 13 - American Association of Pharmaceutical Scientists (AAPS AAPS American Association of Pharmaceutical Scientists AAPS Association of American Physicians and Surgeons AAPS Ann Arbor Public Schools AAPS American Association of Plastic Surgeons AAPS African Association of Political Science ), Toronto, Canada 1) Enhanced Therapeutic Efficacy of a Novel, Liposome-Based Formulation of SN-38 (LE-SN38) (poster presentation) 2) Rapid and Economical Quantitation of Liposome Encapsulated Mitoxantrone (LEM) in Mouse Tissues and Plasma (poster presentation) 3) Enhanced Pharmacokinetics of Mitoxantrone Using An Easy-To-Use (ETU ETU Electrical Trades Union ETU Ethylene Thiourea (pesticide & fungicide) ETU European Taekwondo Union ETU Educational Technology Unit ETU Elementary Time Unit (SIM card timing unit) ) Liposomal Formulation (poster presentation) Friday, November 22 - EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics, Frankfurt, Germany Liposome-Encapsulated c-raf Antisense Oligodeoxynucleotide in Patients with Advanced Solid Tumors: Phase I Study of Weekly Infusion (podium presentation) "We continue to be encouraged by the advancement of our NeoLipid pipeline in pre-clinical and clinical studies. The presentations at these prestigious scientific forums will further highlight the potential value of our compounds," stated James M. Hussey, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. at NeoPharm. Liposomes Liposomes Aqueous compartments enclosed by lipid bilayer membranes; liposomes are also known as lipid vesicles. Phospholipid molecules consist of an elongated nonpolar (hydrophobic) structure with a polar (hydrophilic) structure at one end. are microscopic membrane-like structures created from lipids. They take advantage of tumor cells' need to consume large amounts of fats to sustain the tumor's extremely fast growth. As a result, tumor cells recognize the liposome-encased drug as a potential source of nutrition. Based on NeoPharm's research to date, the NeoLipid formulation has demonstrated an ability to reduce the toxicity of these potent drugs, making for the possibility of a more comfortable to administer, safer, and well-tolerated treatment for cancer patients. In addition, drug stability appears to be significantly enhanced. NeoPharm's NeoLipid technology combines drugs or compounds with proprietary lipids. NeoLipid technology allows for the creation of an exceptionally stable liposome. This physical property is especially important during drug storage and after the product has been reconstituted and administered intravenously to the patient. NeoPharm uses a proprietary synthetic form of cardiolipin. In its natural form, cardiolipin occurs as a negatively charged lipid found in cardiac tissue. When combined with proven anti-cancer agents such as paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); or mitoxantrone, liposome-based drugs appear to improve patient safety and comfort during administration. These liposomes may also help to overcome cancer chemotherapy drug resistance. NeoPharm is a publicly traded biopharmaceutical company dedicated to the research, discovery and commercialization of new and innovative cancer drugs for therapeutic applications. The company has a broad portfolio of compounds in various stages of development. NeoPharm, Inc. +1-847-295-8678 www.neophrm.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion